Dihydropyridine derivatives of the formula ##STR1## wherein the symbols R and R.sup.1 to R.sup.6 have the significance given in claim 1, have a pronounced calcium-antagonist activity and can accordingly be used as medicaments, especially in the control or prevention of angina pectoris, ischemia, high blood pressure and/or migraine. The compounds of formula I can be prepared by reacting an ylidene compound of the formula ##STR2## with an enamine of the formula ##STR3##

Compounds having the structure ##STR1## wherein: R.sup.1 is C.sub.1 -C.sub.8 alkyl; R.sup.2, R.sup.3, R.sup.6 and R.sup.7 are each independently halogen or trihalomethyl; and R.sup.4 and R.sup.5 are halogen, cyano or nitro; are disclosed which have herbicidal activity. Herbicidal compositions comprising the compounds and a carrier are also disclosed, as are methods for controlling the growth of undesirable plants utilizing the compounds. Methods for the preparation of such compounds are also dis...

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and co...

Compounds of the formula ##STR1## inhibit the activity of endothelin. The symbols are defined as follows: R.sup.1, R.sup.2 and R.sup.3 are each independently (a) hydrogen, except that R.sup.1 is other than hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3 ; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) --C(O)H or --C(O)R.sup.6 ; (h) ...

A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.

Recombinant proteins comprising on or more mitochondrial leader peptide sequences and a domain having herbicidal sulfonamide-insensitive dihydropteroate synthase activity are disclosed. Transformation of plants with nucleic acids that encode this mitochondrially-targeted recombinant protein is also provided. Such transformed plants exhibit resistance to herbicidal sulfonamides, such as asulam, and therefore may be cultivated where such herbicides are being used to control weed growth.

This invention relates to herbicidal N-(heterocyclylcarbonyl)sulfonamide compounds, compositions comprising N-(heterocyclylcarbonyl)sulfonamide herbicides and an agronomically acceptable carrier, and the use thereof as broad spectrum herbicides which are effective against both monocot and dicot weed species in both preemergence and postemergence applications. This invention also teaches methods of preparing these compounds as well as methods of using the compounds as herbicides.

Described are fluorochemical surfactants derived from nonafluorobutanesulfonyl fluoride that contain polyalkyleneoxy side chains and may be copolymerized with acrylic acid or methacrylic acid to form polyacrylates or polymethacrylates. The surfactants surprisingly lower the surface tension of water and other liquids in the same or similar low values achieved by premier surfactants such as those derived from perfluorooctane sulfonyl fluoride.

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

The present invention relates to novel cysteine protease inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making.